And We Wonder Why Patients Get Confused…

1020px-S10-5263_H&E_20x_DCIS

How often have we heard people lament about the inherent contradictions in cancer research? How often do people throw up their arms and say “I don’t know what to believe anymore”. Too many people harbour the feeling that whatever some study shows today will be contradicted by a study published next month and so on and so on. What too many folks fail to appreciate is that this is actually science and research working as …

     

Of “Ground-Breaking” and “Breakthrough” and “Blockbuster”: Endpoints Matter

Breakthrough

This week in San Diego the American Association for Cancer Research is holding its annual meeting. When I was an active cancer researcher this was one of the premier meetings that I made sure I attended if at all possible. The meeting itself is high enough profile that many top researchers from around the world wait to announce significant results at this meeting, because they know that the rest of the cancer research world will …

     

New Promise for Detecting Ovarian Cancers Earlier

Some very encouraging news broke today in the fight to detect ovarian cancers earlier. Often called “the silent killer” or the “disease that whispers” ovarian cancer often first presents itself when it is already at an advanced stage and when the prognosis is not very favourable. The irony is that women whose ovarian cancers are caught early in Stage I have excellent 5-year survival rates, in excess of 80-90%. In this case, the earlier the …

     

Novartis’ Cancer Drug (Gleevec) vs. the Supreme Court of India: a Classic Catch-22?

Indian Supreme Court

The ruling the other day by the Indian Supreme Court to deny Swiss global pharmaceutical company Novartis AG’s patent appeal for its cancer drug Gleevec (Imatinib) has been called landmark for many reasons. In fact, there have been dozens, if not hundreds of articles in newspapers, journals, blogs and much coverage in all media. Here are but a few examples that are not intended by any means to be exhaustive but merely illustrative of the …